"Ms. Carrithers and I are intimately familiar with the unique requirements of cancer research centers and institutional IRBs," said Ms. Russell-Einhorn. "COR combines our deep understanding of this environment with Schulman IRB's best-in-class customer service and compliance record, providing cancer research centers and their IRBs with unparalleled transparency and collaboration throughout the review process."
Recent regulatory activities, like NIH's single IRB policy and HHS' proposed changes to the "Common Rule," will require multicenter research studies to be overseen by a central IRB. The challenges of managing a centralized IRB review process have encouraged many research institutions to seek working relationships with external IRBs.
"We know that a one-size-fits-all approach won't work for institutions," said Michael Woods, President and CEO at Schulman IRB. "COR will customize services to meet each institution's needs, providing levels of reliable, sophisticated support far beyond what is currently available in the central IRB space."
At Johns Hopkins, Ms. Carrithers was responsible for the direct operations of 7 IRBs, and she helped develop and manage the Johns Hopkins Clinical Research Network collaboration between Johns Hopkins and 5 regional hospitals. She also coordinated with the University's General Counsel, IRB chairs and administration to develop policies and procedures for the IRBs, affiliated hospitals, and more than 20 ancillary review committees. She led initiatives to create more efficient and effective IRB processes at Johns Hopkins and also collaborated with Sun Yat-sen University in Guangzhou, China, to assess and improve that university's clinical research capabilities.
About Central Oncology Review (COR)
COR provides collaborative, flexible central IRB review services for cancer research centers and their IRBs, offering an advanced level of partnership and service integration. COR's staff and IRB members include research professionals and clinicians with significant firsthand experience in contemporary oncology research and the associated unique human subject protection requirements. Powered by Schulman IRB's best-in-class customer service and technology, COR offers unmatched IRB expertise and efficiency in support of institutions at the cutting edge of oncology research. COR launches later in 2016.
About Schulman IRB
Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services through its Provision Research Compliance Services division, offering comprehensive solutions to maximize the protection of human subjects and improve overall quality standards for clinical studies and data integrity. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).
For more information, please visit http://www.sairb.com or follow @SchulmanIRB on Twitter or on LinkedIn.
Logo - http://photos.prnewswire.com/prnh/20160125/325578LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/schulman-irbs-central-oncology-review-cor-division-adds-another-institutional-research-leader-to-team-300336661.html
SOURCE Schulman IRB